PUMA BIOTECHNOLOGY, INC. (PBYI) EBITDA
- 2026-06-30: Basis Reported; EBITDA (m); Operating income $7.58M; Depreciation and amortization (m).
- 2026-03-31: Basis Reported; EBITDA (m); Operating income -$3.83M; Depreciation and amortization (m).
- 2025-09-30: Basis Reported; EBITDA (m); Operating income $9.57M; Depreciation and amortization (m).
- 2025-06-30: Basis Reported; EBITDA (m); Operating income $6.64M; Depreciation and amortization (m).
Historical EBITDA
EBITDA 3 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | Reported | (m) | $7.58M | (m) | $56.50M | (m) | $0.00* | $1.62M* | $12.47M | (m) | $17.55M | (m) |
| 2026-03-31 | Reported | (m) | -$3.83M | (m) | $44.81M | (m) | $0.00 | $15.42M | $10.42M | (m) | $18.42M | (m) |
| 2025-09-30 | Reported | (m) | $9.57M | (m) | $54.48M | (m) | $26.00K* | $9.69M* | $12.17M | (m) | $16.82M | (m) |
| 2025-06-30 | Reported | (m) | $6.64M | (m) | $52.44M | (m) | $20.00K* | $14.08M* | $12.30M | (m) | $18.05M | (m) |
| 2025-03-31 | Reported | (m) | $3.98M | (m) | $46.01M | (m) | $61.00K | $3.61M | $10.56M | (m) | $17.60M | (m) |
| 2024-09-30 | Reported | (m) | $22.08M | (m) | $80.54M | (m) | $20.00K* | $11.04M* | $29.10M | (m) | $16.82M | $291.00K |
| 2024-06-30 | Reported | (m) | -$2.18M | (m) | $47.08M | (m) | $20.00K* | $1.03M* | $10.66M | (m) | $24.97M | $378.00K |
| 2024-03-31 | Reported | (m) | -$2.30M | (m) | $43.77M | (m) | $0.00 | $11.25M | $10.73M | (m) | $21.75M | $220.00K |
| 2023-09-30 | Reported | (m) | $8.59M | (m) | $56.12M | (m) | $27.00K* | $10.62M* | $13.28M | (m) | $22.80M | $213.00K |
| 2023-06-30 | Reported | (m) | $4.89M | (m) | $54.57M | (m) | (m) | $3.30M* | $11.86M | (m) | $24.46M | $187.00K |
| 2023-03-31 | Reported | (m) | $4.37M | (m) | $52.77M | (m) | (m) | $2.64M | $13.22M | (m) | $22.49M | $147.00K |
| 2022-09-30 | Reported | (m) | $2.39M | (m) | $57.10M | (m) | $0.00* | $17.26M* | $12.49M | (m) | $23.96M | $67.00K |
| 2022-06-30 | Reported | (m) | $12.06M | (m) | $59.52M | (m) | (m) | -$13.87M* | $14.92M | $11.97M | $20.58M | $57.00K |
| 2022-03-31 | Reported | (m) | -$747.00K | (m) | $45.74M | (m) | (m) | -$26.89M | $10.84M | $15.24M | $20.40M | $37.00K |
| 2021-09-30 | Reported | (m) | -$8.95M | (m) | $46.24M | (m) | (m) | $10.50M* | $10.28M | $18.84M | $26.08M | $37.00K |
| 2021-06-30 | Reported | (m) | -$16.63M | (m) | $53.38M | (m) | (m) | -$74.00K* | $11.97M | $18.64M | $39.41M | $38.00K |
| 2021-03-31 | Reported | (m) | $20.15M | (m) | $98.17M | (m) | (m) | $15.66M | $29.56M | $20.23M | $28.24M | $38.00K |
| 2020-09-30 | Reported | (m) | -$12.13M | (m) | $50.75M | (m) | $11.00K* | $1.72M* | $9.94M | $23.34M | $29.60M | $0.00 |
| 2020-06-30 | Reported | (m) | $7.13M | (m) | $70.58M | (m) | (m) | $16.23M* | (m) | $24.69M | $29.35M | (m) |
| 2020-03-31 | Reported | (m) | -$14.25M | (m) | $51.22M | (m) | (m) | -$11.54M | (m) | $25.45M | $30.94M | (m) |
| 2019-09-30 | Reported | (m) | -$14.45M | (m) | $56.35M | (m) | (m) | -$7.31M* | (m) | $30.03M | $31.40M | (m) |
| 2019-06-30 | Reported | (m) | -$25.78M | (m) | $53.92M | (m) | (m) | $44.25M* | $9.32M | $36.85M | $33.53M | (m) |
| 2019-03-31 | Reported | (m) | $9.85M | (m) | $99.07M | (m) | (m) | -$16.13M | $7.99M | $35.73M | $45.51M | (m) |
| 2018-09-30 | Reported | (m) | -$11.28M | (m) | $62.63M | (m) | $305.00K* | -$7.26M* | $9.05M | $36.36M | $28.50M | (m) |
| 2018-06-30 | Reported | (m) | -$41.44M | (m) | $50.77M | (m) | $205.00K* | -$17.64M* | $8.83M | $43.24M | $40.13M | (m) |
| 2018-03-31 | Reported | (m) | -$23.39M | (m) | $66.52M | (m) | $40.00K | -$6.25M | $6.38M | $46.92M | $36.60M | (m) |
| 2017-09-30 | Reported | (m) | -$77.44M | (m) | $6.08M | (m) | $154.00K* | -$54.91M* | $1.53M | $49.50M | $32.49M | (m) |
| 2017-06-30 | Reported | (m) | -$78.18M | (m) | (m) | (m) | $8.00K* | (m) | (m) | $53.25M | $24.93M | (m) |
| 2017-03-31 | Reported | (m) | -$73.20M | (m) | (m) | (m) | $124.00K | (m) | (m) | $54.80M | $18.40M | (m) |
| 2016-09-30 | Reported | (m) | -$66.00M | (m) | (m) | (m) | $65.00K* | (m) | (m) | $51.98M | $14.02M | (m) |
| 2016-06-30 | Reported | (m) | -$66.48M | (m) | (m) | (m) | $3.62M* | (m) | (m) | $54.22M | $12.27M | (m) |
| 2016-03-31 | Reported | (m) | -$71.25M | (m) | (m) | (m) | $44.00K | (m) | (m) | $60.21M | (m) | (m) |
| 2015-09-30 | Reported | (m) | -$60.73M | (m) | (m) | (m) | $152.00K* | (m) | (m) | $51.92M | (m) | (m) |
| 2015-06-30 | Reported | (m) | -$64.91M | (m) | (m) | (m) | $356.00K* | (m) | (m) | $59.38M | (m) | (m) |
| 2015-03-31 | Reported | (m) | -$52.60M | (m) | (m) | (m) | $435.00K | (m) | (m) | $44.73M | (m) | (m) |
| 2014-09-30 | Reported | (m) | -$35.96M | (m) | (m) | (m) | $128.00K* | (m) | (m) | $32.09M | (m) | (m) |
| 2014-06-30 | Reported | (m) | -$38.91M | (m) | (m) | (m) | (m) | (m) | (m) | $35.00M | (m) | (m) |
| 2014-03-31 | Reported | (m) | -$19.82M | (m) | (m) | (m) | (m) | -$17.05M | (m) | $16.29M | (m) | (m) |
| 2013-09-30 | Reported | (m) | -$14.33M | (m) | (m) | (m) | (m) | -$12.00M | (m) | $12.07M | (m) | (m) |
| 2013-06-30 | Reported | (m) | -$12.71M | (m) | (m) | (m) | (m) | -$11.00M | (m) | $10.44M | (m) | (m) |
| 2013-03-31 | Reported | (m) | -$11.81M | (m) | (m) | (m) | (m) | -$18.48M | (m) | $9.53M | (m) | (m) |
| 2012-09-30 | Reported | (m) | -$25.87M | (m) | (m) | (m) | (m) | -$7.64M* | (m) | $17.78M | (m) | (m) |
| 2012-06-30 | Reported | (m) | -$14.78M | (m) | (m) | (m) | $240.52K* | -$8.77M | (m) | $13.01M | (m) | (m) |
| 2012-03-31 | Reported | (m) | -$11.85M | (m) | (m) | (m) | $187.17K | -$2.79M | (m) | $10.57M | (m) | (m) |
| 2011-09-30 | Reported | (m) | -$333.93K | (m) | (m) | (m) | $0.00* | -$143.22K* | (m) | (m) | (m) | (m) |
| 2011-06-30 | Reported | (m) | -$34.27K | (m) | (m) | (m) | (m) | -$35.99K* | (m) | (m) | (m) | (m) |
| 2011-03-31 | Reported | (m) | -$3.94K | (m) | (m) | (m) | (m) | -$3.94K | (m) | (m) | (m) | (m) |
| 2010-12-31 | Reported | (m) | -$6.93K | (m) | (m) | (m) | (m) | -$6.93K | (m) | (m) | (m) | (m) |
| 2010-12-31 | Reported | (m) | -$7.00K | (m) | (m) | (m) | (m) | -$7.00K | (m) | (m) | (m) | (m) |
| 2010-09-30 | Reported | (m) | -$6.63K | (m) | (m) | (m) | (m) | $2.77K* | (m) | (m) | (m) | (m) |
EBITDA 12 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | Reported | (m) | $37.30M | (m) | $228.37M | (m) | $71.00K | $41.80M | $58.16M | (m) | $70.85M | $4.67M |
| 2024-12-31 | Reported | (m) | $30.97M | (m) | $230.47M | (m) | $56.00K | $38.92M | $64.40M | (m) | $80.16M | -$6.18M |
| 2023-12-31 | Reported | (m) | $32.64M | (m) | $235.64M | (m) | $140.00K | $27.01M | $62.68M | (m) | $89.93M | $1.08M |
| 2022-12-31 | Reported | (m) | $23.72M | (m) | $228.03M | (m) | $0.00 | -$15.83M | $55.09M | (m) | $89.98M | $455.00K |
| 2021-12-31 | Reported | (m) | $1.29M | (m) | $253.16M | (m) | $0.00 | $20.65M | $63.70M | $71.87M | $116.29M | $324.00K |
| 2020-12-31 | Reported | (m) | -$30.40M | (m) | $225.11M | (m) | $46.00K | $773.00K | $39.37M | $97.65M | $118.49M | $207.00K |
| 2019-12-31 | Reported | (m) | -$39.05M | (m) | $272.26M | (m) | $306.00K | $22.38M | $36.81M | $132.85M | $141.64M | $53.00K |
| 2018-12-31 | Reported | (m) | -$94.66M | (m) | $250.99M | (m) | $439.00K | -$24.11M | $34.62M | $164.85M | $146.17M | $17.00K |
| 2017-12-31 | Reported | (m) | -$292.39M | (m) | $27.68M | (m) | $431.00K | -$172.47M | $5.57M | $207.81M | $106.69M | $0.00 |
| 2016-12-31 | Reported | (m) | -$276.60M | (m) | (m) | (m) | $4.29M | -$141.69M | (m) | $222.80M | $53.80M | $0.00 |
| 2015-12-31 | Reported | (m) | -$240.28M | (m) | (m) | (m) | $1.00M | (m) | (m) | $208.47M | $31.81M | $0.00 |
| 2014-12-31 | Reported | (m) | -$142.28M | (m) | (m) | (m) | $1.10M | (m) | (m) | $122.92M | (m) | $0.00 |
| 2013-12-31 | Reported | (m) | -$54.83M | (m) | (m) | (m) | $624.00K | -$55.05M | (m) | $45.05M | (m) | $0.00 |
| 2012-12-31 | Reported | (m) | -$74.45M | (m) | (m) | (m) | (m) | -$44.01M | (m) | $49.64M | (m) | $0.00 |
| 2011-12-31 | Reported | (m) | -$10.16M | (m) | (m) | (m) | $253.33K | -$1.82M | (m) | $826.00K | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |